Chronic News and Research

RSS

British scientist wins NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation (NYSCF) announced today that a British stem cell scientist working to cure blindness will be the first recipient of The New York Stem Cell Foundation - Robertson Prize in Stem Cell Research, a $200,000 prize awarded annually for extraordinary achievement in translational stem cell research.

12 Oct 2011

Roundup: Calif. insurer's Avastin decision; Kansas dental care; Gov. Brown vetoes nursing bill

Blue Shield of California will stop covering new Avastin prescriptions for breast cancer patients starting Oct. 17. Patients already on the drug will still be covered, and exceptions could be made for individual cases reviewed by a panel of cancer experts. The not-for-profit insurer cited an unprecedented vote by a U.S. Food and Drug Administration panel that found the drug was not effective enough against breast cancer to risk its potentially dangerous side effects.

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Multivitamin supplements no panacea for women: Study

According to the latest American study women who take multivitamin supplements don't live longer than those who get their nutrients from food alone. In fact, they appear to have slightly higher death rates, researchers found.

11 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

CRN responds to study on dietary supplements in older women

In response to the published study, "Dietary Supplements and Mortality Rate in Older Women," published in the Archives of Internal Medicine (a publication of the American Medical Association), the Council for Responsible Nutrition (CRN), the leading trade association representing the dietary supplement industry, issued the following two-part statement.

11 Oct 2011

Tantalizing glimmers about roles of CCR2 gene, Th17 cell and a missing monocyte

An estimated 1.3 million people in the United States suffer from rheumatoid arthritis. The causes behind this chronic disease — which can exhibit itself as pain, swelling, stiffness, deformation, and loss of function in the joints — have eluded scientists for centuries. A new study by UNC researchers offers tantalizing glimmers about the roles of a gene called CCR2, an immune system cell called Th17 cell, and a missing monocyte.

11 Oct 2011

Aspirin desensitization procedure can benefit patients with sinusitis, asthma and AERD

Beth Moore can now keep up with her children. The suburban Philadelphia mother of two had suffered from allergies and chronic sinusitis since her teens. With age her symptoms became more severe, turning into bronchitis and eventually asthma, diminishing her ability to breathe and sapping her of her energy. The only complete relief came from aspirin; and the aspirin desensitization that allowed her to overcome her aspirin allergy and end her decades-long battle with sinusitis.

11 Oct 2011

Scripps Research receives NIH grant to determine how HCV induces liver cancer

The Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of Health (NIH) to determine how the hepatitis C virus (HCV) induces liver cancer.

11 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Case Western Reserve wins NCI grant to study genetic determinants of esophageal cancer

Case Western Reserve University School of Medicine and the Case Comprehensive Cancer Center are proud to announce the receipt of a highly competitive $5.4 million grant to study genetic determinants of Barrett's esophagus and esophageal adenocarcinoma.

11 Oct 2011

Merck’s diabetes combo pill gets FDA nod

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

10 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011

AIT Laboratories introduces new suite of services for prescription compliance monitoring

Chronic pain affects an estimated 116 million adults in the U.S.—more than the number affected by heart disease, diabetes, and cancer combined, according to a recent report by the Institute of Medicine.

10 Oct 2011

Ford researchers develop series of in-car health and wellness apps, services

Researchers at Ford have developed a series of in-car health and wellness apps and services aimed at monitoring people with chronic illnesses or medical disorders so they can manage their condition while on the go.

From Medtronic 10 Oct 2011

Pharmasset adds two treatment arms to PSI-7977 ELECTRON trial on HCV

Pharmasset, Inc. announced today the addition of two treatment arms to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C.

10 Oct 2011

Patients with AF can benefit from Medtronic Phased RF Ablation System ablation system

Medtronic, Inc. today announced results from its Tailored Treatment of Permanent Atrial Fibrillation clinical trial, the first randomized study comparing ablation therapy with the Medtronic Phased RF Ablation System ablation system to traditional medical management in 210 patients with persistent or long-standing persistent atrial fibrillation.

From Medtronic 10 Oct 2011

Lack of sleep during adolescence could lead to more than dragging, foggy teens

An ongoing lack of sleep during adolescence could lead to more than dragging, foggy teens, a University of Wisconsin-Madison study suggests.

10 Oct 2011

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

10 Oct 2011